“Dystrophic Epidermolysis Bullosa Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dystrophic Epidermolysis Bullosa Market.

The Dystrophic Epidermolysis Bullosa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Dystrophic Epidermolysis Bullosa Pipeline Report:

• Companies across the globe are diligently working toward developing novel Dystrophic Epidermolysis Bullosa treatment therapies with a considerable amount of success over the years. Dystrophic Epidermolysis Bullosa Key players such as – Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., InMed Pharmaceuticals Inc., and others, are developing therapies for the Dystrophic Epidermolysis Bullosa treatment

• Dystrophic Epidermolysis Bullosa Emerging therapies such as – VYJUVEK (beremagene geperpavec), FILSUVEZ (birch triterpenes), PTW-002 10 mg/g gel, AGLE 102, ALLO-ASC-SHEET, EB-101, FCX-007, PTR-01, SD-101-6.0 cream, INM-755 (cannabinol) cream, and others are expected to have a significant impact on the Dystrophic Epidermolysis Bullosa market in the coming years.

• In May 2025, The US Food and Drug Administration (FDA) has granted approval to Zevaskyn™ (prademagene zamikeracel), marking it as the first autologous cell-based gene therapy for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). Known as pz-cel, this therapy involves a single surgical application of cell sheets. According to Abeona Therapeutics, the treatment utilizes a patient’s own keratinocyte cells, which are genetically engineered to produce functional Type VII collagen. This approval comes shortly after the FDA authorized another innovative therapy aimed at treating a chronic skin disorder—chronic spontaneous urticaria.

• In April 2025, Abeona Therapeutics Inc. (Nasdaq: ABEO) has announced that the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN™ (prademagene zamikeracel), also known as pz-cel, as the first and only autologous cell-based gene therapy for treating wounds in both adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). This rare and debilitating genetic skin disorder currently has no cure, and ZEVASKYN stands as the only FDA-approved treatment offering wound healing through a single application.

• In April 2025, The FDA has granted approval to prademagene zamikeracel (Zevaskyn; Abeona Therapeutics), marking it as the first and only autologous cell-based gene therapy for treating wounds in both adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), according to a press release by Abeona Therapeutics. The approval is supported by results from the pivotal Phase 3 VIITAL study (NCT04227106)—a multicenter, randomized, intrapatient-controlled trial—where the therapy showed statistically significant healing of at least 50% in large, chronic RDEB wounds and a notable reduction in pain from baseline, measured using the Wong-Baker FACES scale, six months after treatment.

Dystrophic Epidermolysis Bullosa Overview

Dystrophic epidermolysis bullosa, or DEB, is an incurable, often fatal skin blistering condition caused by a lack of collagen protein in the skin. It is caused by mutations in the COL7A1 gene encoding type VII collagen, or COL7, a major component of anchoring fibrils which connect the epidermis to the underlying dermis and provide structural adhesion between these skin layers in a healthy individual.

Get a Free Sample PDF Report to know more about Dystrophic Epidermolysis Bullosa Pipeline Assessment-

https://www.delveinsight.com/report-store/dystrophic-epidermolysis-bullosa-pipeline-insight

Emerging Dystrophic Epidermolysis Bullosa Drugs Under Different Phases of Clinical Development Include:

• VYJUVEK (beremagene geperpavec): Krystal Biotech

• FILSUVEZ (birch triterpenes): Chiesi

• PTW-002 10 mg/g gel: Phoenicis Therapeutics

• AGLE 102: Aegle Therapeutics

• ALLO-ASC-SHEET: Anterogen Co., Ltd.

• EB-101: Abeona Therapeutics, Inc

• FCX-007: Castle Creek Bioscience

• PTR-01: Phoenix Tissue Repair, Inc.

• SD-101-6.0 cream: Scioderm, Inc.

• INM-755 (cannabinol) cream: InMed Pharmaceuticals Inc.

Dystrophic Epidermolysis Bullosa Pipeline Therapeutics Assessment

• Dystrophic Epidermolysis Bullosa Assessment by Product Type

• Dystrophic Epidermolysis Bullosa By Stage and Product Type

• Dystrophic Epidermolysis Bullosa Assessment by Route of Administration

• Dystrophic Epidermolysis Bullosa By Stage and Route of Administration

• Dystrophic Epidermolysis Bullosa Assessment by Molecule Type

• Dystrophic Epidermolysis Bullosa by Stage and Molecule Type

DelveInsight’s Dystrophic Epidermolysis Bullosa Report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Download Sample PDF Report to know more about Dystrophic Epidermolysis Bullosa drugs and therapies

Dystrophic Epidermolysis Bullosa Pipeline Analysis:

The Dystrophic Epidermolysis Bullosa pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the Dystrophic Epidermolysis Bullosa treatment with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dystrophic Epidermolysis Bullosa Treatment.

• Dystrophic Epidermolysis Bullosa key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Dystrophic Epidermolysis Bullosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dystrophic Epidermolysis Bullosa market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Dystrophic Epidermolysis Bullosa product details are provided in the report. Download the Dystrophic Epidermolysis Bullosa pipeline report to learn more about the emerging Dystrophic Epidermolysis Bullosa therapies

Dystrophic Epidermolysis Bullosa Pipeline Market Drivers

• Improving Healthcare Infrastructure

• Demand for New and Effective Drugs

Dystrophic Epidermolysis Bullosa Pipeline Market Barriers

• Currently no cure for all types of dystrophic epidermolysis bullosa (DEB)

• Making a diagnosis for a genetic or rare disease is often challenging

Scope of Dystrophic Epidermolysis Bullosa Pipeline Drug Insight

• Coverage: Global

• Key Dystrophic Epidermolysis Bullosa Companies: Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., InMed Pharmaceuticals Inc., and others

• Key Dystrophic Epidermolysis Bullosa Therapies: VYJUVEK (beremagene geperpavec), FILSUVEZ (birch triterpenes), PTW-002 10 mg/g gel, AGLE 102, ALLO-ASC-SHEET, EB-101, FCX-007, PTR-01, SD-101-6.0 cream, INM-755 (cannabinol) cream, and others

• Dystrophic Epidermolysis Bullosa Therapeutic Assessment: Dystrophic Epidermolysis Bullosa current marketed and Dystrophic Epidermolysis Bullosa emerging therapies

• Dystrophic Epidermolysis Bullosa Market Dynamics: Dystrophic Epidermolysis Bullosa market drivers and Dystrophic Epidermolysis Bullosa market barriers

Request for Sample PDF Report for Dystrophic Epidermolysis Bullosa Pipeline Assessment and clinical trials

Table of Contents

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/